Beta-lactam dose reductions in critically ill patients with acute kidney injury: a scoping review - Quiz - MDSpire

Beta-lactam dose reductions in critically ill patients with acute kidney injury: a scoping review

  • By

  • M. M.B. Horstink

  • W. J.R. Rietdijk

  • D. R. Geel

  • P. E. Deetman

  • H. Endeman

  • B. C.P. Koch

  • C. A. den Uil

  • December 2, 2025

  • 0 min

Share

Original Source(s)

Beta-lactam dose reductions in critically ill patients with acute kidney injury: a scoping review

  • by M. M.B. Horstink, W. J.R. Rietdijk, D. R. Geel, P. E. Deetman, H. Endeman, B. C.P. Koch, C. A. den Uil

  • December 2, 2025

Related Content

Complement in acute kidney injury: a convergent pathogenic pathway in multifactorial renal damage

Soluble CD147 in Plasma During Sepsis: Correlation with Disease Severity and Prognostic Implications

The regulatory mechanism of NLRP3 inflammasome in the “immune paralytic-overactivation” imbalance in sepsis: the latest progress from molecular signaling to clinical translation